

# PE-Labeled Human HLA-A\*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein



Cat. No. MHC-HM421TP

## Description

**Source** Recombinant PE-Labeled Human HLA-A\*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. PE-labeled Human HLA-A\*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer is assembled by biotinylated monomer and PE-Labeled streptavidin.

It contains Gly25-Thr305(HLA-A\*11:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide.

**Accession** AAV53343.1(HLA-A\*11:01)&P61769(B2M)&VVVGAVGVGK

**Wavelength** Excitation Wavelength: 488 nm / 561 nm

Emission Wavelength: 575 nm

**Endotoxin** Less than 1EU per µg by the LAL method.

## Formulation and Storage

**Formulation** Supplied as 0.22µm filtered solution in PBS, 0.2% BSA (pH 7.4).

**Storage** Valid for 6 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

## Background

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.